UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
On April 13, UBS Group AG raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $27 from $25. It maintained a Neutral rating on the shares. The update came as part of the firm's Q1 preview for the pharmaceuticals and biotechnology group, where it adjusted its targets. During its Q4 2025 earnings call, Pfizer stuck with its 2026 outlook. It expects revenue to land between $59.5 billion and $62.5 billion. Adjusted diluted EPS is still projected in the range of $2.80 to $3.00 for the year. CFO David Denton said COVID-related products will decline further in 2026, with revenue expected at around $5 billion. He noted that the non-COVID portfolio should hold steady, though it includes an estimated $1.5 billion headwind from products facing generic competition. He added that, at the midpoint of guidance, revenue excluding COVID products and those impacted by loss of exclusivity is expected to grow roughly 4% on an operational basis compared to last year. Management also said it i
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (PFE) is now covered by CICC Research. They set an "outperform" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of ShareholdersBusiness Wire
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- 4/1/26 - Form 4
- PFE's page on the SEC website